Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the American Society of Nephrology (ASN) Kidney Week 2022
- Updated interim data to be presented from the IgA nephropathy (IgAN) patient cohort of the atrasentan phase 2 AFFINITY basket trial
- Additional interim data to be presented from Cohorts 1 and 2 of the ongoing phase 1/2 study of BION-1301 in patients with IgAN
- Research presentations include the preclinical efficacy profile of CHK-336 and multiple abstracts detailing
Chinook's multidimensional approach to precision medicine in nephrology
Chinook to host investor conference call and webcast onNovember 4, 2022 to review and discuss the abstracts and provide corporate updates
Poster Presentations
TH-PO497: |
Atrasentan for the Treatment of IgA Nephropathy: Interim Results from the AFFINITY Study |
|
Presenting Author: | ||
Session Title: | Glomerular Diseases: Clinical, Outcomes, Trials - I | |
Session Time: |
FR-PO659: | Updated Interim Results of a Phase 1/2 Study of BION-1301 in Patients with IgA Nephropathy | |
Presenting Author: | ||
Session Title: | Glomerular Diseases: Clinical, Outcomes, Trials - II | |
Session Time: |
TH-PO419: | Single Nuclei RNA-seq Reveals Cell-type Specific Responses to Disease and Enalapril in the gddY Mouse Model of IgAN | |
Presenting Author: | ||
Session Title: | Glomerular Diseases: Inflammation and Fibrosis | |
Session Time: |
FR-PO334: | Preclinical Efficacy of CHK-336: A First in Class, Liver-Targeted, Small Molecule Inhibitor of Lactate Dehydrogenase for the Treatment of Primary Hyperoxalurias | |
Presenting Author: | ||
Session Title: | Genetic Diseases: Models, Mechanisms, Treatments | |
Session Time: |
SA-PO1011: | Unsupervised Characterization of the NURTuRE Cohort Reveals Gene Expression and Tissue Remodeling Dynamics along a Synthetic CKD Progression Axis | |
Presenting Author: | Tobias Bohnenpoll, Ph.D., Evotec SE | |
Session Title: | CKD Pathobiology - II | |
Session Time: |
Oral Presentation
FR-OR60: | A Multi-Omics Approach to IgA Nephropathy Characterization in the NURTuRE Cohort Enables Precision-Based Treatment Approaches | |
Presenting Author: | ||
Session Title: | Glomerular Diseases: From Bench to Bedside | |
Session Time: |
Informational Posters
INFO27: | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients with IgA Nephropathy – The ALIGN Study | |
Presenting Author: | Hiddo Heerspink, Ph.D., |
|
Session Time: |
INFO31: | Atrasentan in Patients with Proteinuric Glomerular Diseases – The AFFINITY Study | |
Presenting Author: | ||
Session Time: |
INFO28: | A Phase 1/2 Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BION-1301 in |
|
Presenting Author: | ||
Session Time: |
For more information on these and other abstracts, please visit the ASN Kidney Week 2022 website.
Investor Conference Call Details
To access the call, please dial (800) 715-9871 (domestic) or (646) 307-1963 (international) and provide the Conference ID 7505851 to the operator.
To access the live webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Chinook’s website. The archived webcast will remain available for replay on Chinook’s website for 90 days.
About
Contact:Noopur Liffick Vice President, Investor Relations & Corporate Communications investors@chinooktx.com media@chinooktx.com
Source: Chinook Therapeutics, Inc.